<![CDATA[PD-1/VEGF Bispecific Antibody Receives FDA Fast Track Designation in NSCLC]]>

RegulatorycesalatamigPositive

AI Analysis

Summary

Cesalatamig, a PD-1/VEGF bispecific antibody, received FDA Fast Track Designation for advanced NSCLC. The drug is being evaluated in the international phase 1/2 BiPAVE-001 trial.

Clinical Trial Data

Phase

1/2

Outcome Details

FDA Fast Track Designation granted

Importance:6/10

Sentiment:

0.70

PD-1/VEGF bispecific antibodyFast Track DesignationNSCLCAdvanced cancerBiPAVE-001

Related Companies

$ISCO

Read the original article

Published by Cancer Network on September 17, 2026 3:30 PM

Read Original